Ankang is a multi-disciplined seasoned executive and strategic leader with expertise spanning multiple healthcare business sectors.

His executive leadership includes Chief Financial and Strategy roles at various biotechnology companies, including Brii Biosciences and Terns Pharmaceuticals. This financial expertise is anchored by his tenure as an Executive Director of Healthcare Investment Banking at Goldman Sachs, where he successfully led many high-profile biotech IPOs.

Ankang’s academic foundation includes a Juris Doctor (J.D.) from the University of Chicago Law School, a Ph.D. in Biomedical Sciences from Baylor College of Medicine, a Master of Science (M.S.) from the National University of Singapore, and an undergraduate degree in Biochemistry from Fudan University. He also holds a Chartered Financial Analyst (CFA) designation, providing a unique, integrated perspective across science, law, and finance.

This perspective proves invaluable when guiding portfolio companies toward successful exits, as Ankang understands what drives strategic value creation from both the buyer and seller perspectives.